Oritinib
Oritinib (SH-1028), an irreversible third-generation EGFR TKI, overcomes T790M-mediated resistance in non-small cell lung cancer. Oritinib (SH-1028), a mutant-selective inhibitor of EGFR kinase activity, inhibits EGFRWT, EGFRL858R, EGFRL861Q, EGFRL858R/T790M, EGFRd746-750 and EGFRd746-750/T790M kinases, with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM, respectively[1].
Product Specifications
CAS Number
2035089-28-0
Product Name Alternative
SH-1028
UNSPSC
12352005
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/oritinib.html
Concentration
10mM
Purity
99.59
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC(NC2=NC(C3=C(CCCC4)N4C5=C3C=CC=C5)=CC=N2)=C(C=C1N(CCN(C)C)C)OC)C=C
Molecular Formula
C31H37N7O2
Molecular Weight
539.67
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
EGFR/ErbB1/HER1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
ReadiLink™ Rapid iFluor® 647 Antibody Labeling Kit *Production Scale*
Staphylococcal aureus Enterotoxin Total (SET) ELISA Kit
![APC Anti-Mouse FcεRIα Antibody[MAR-1]](https://cdn.genprice.uk/products/763/68dd1496061270361e7cdb50/imageurl/e-ab-f1188ue.webp)